Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Breaking cone of silence around 351(k) applications with passed user fee dates, Hospira parent Pfizer says additional clinical trials not needed following complete response letter for epoetin alfa biosimilar.
You may also be interested in...
Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear
First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.
Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear
First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.
Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count
The latest drug development news and US FDA highlights from our Performance Tracker.